|drug790||Covid-19 presto test Wiki||0.71|
|drug2606||Serology for Covid-19 Wiki||0.71|
|D018410||Pneumonia, Bacterial NIH||0.71|
|D008173||Lung Diseases, Obstructive NIH||0.24|
|D008171||Lung Diseases, NIH||0.17|
|D011024||Pneumonia, Viral NIH||0.09|
|D045169||Severe Acute Respiratory Syndrome NIH||0.07|
|D018352||Coronavirus Infections NIH||0.06|
There are 2 clinical trials
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
Description: The percent of samples from the fully enrolled cohort to return a valid SARS-CoV-2 test result (positive, not detected, or inconclusive)Measure: Valid SARS-CoV-2 Test Time: Subjects are assessed at enrollment
The purpose of this research study is 1) to conduct a prospective longitudinal surveillance research trial, enrolling up to 200 CCHMC employees as they come back to work, and then following their clinical and laboratory parameters for up to 12 months; and 2) to support the ongoing development of diagnostic techniques for COVID-19. The overall goal is to investigate patterns of SARS-COV-2 infection, including immunological recovery and genetic risk factors, among CCHMC employees to better understand how to safely reintroduce the CCHMC work force back into their normal routines.
Description: Acquired COVID is defined as testing negative for COVID at baseline and having 1 or more weekly nasal swab samples testing positive for the virus by PCRMeasure: The 6-month cumulative incidence of acquired COVID infection in the study cohort. Time: Weekly for 6 months